Henry Schein Inc (HSIC) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Henry Schein Inc stock (HSIC) is currently trading at $74.25. Henry Schein Inc PE ratio is 22.64. Henry Schein Inc PS ratio (Price-to-Sales) is 0.66. Analyst consensus price target for HSIC is $90.00. WallStSmart rates HSIC as Hold.
- HSIC PE ratio analysis and historical PE chart
- HSIC PS ratio (Price-to-Sales) history and trend
- HSIC intrinsic value — DCF, Graham Number, EPV models
- HSIC stock price prediction 2025 2026 2027 2028 2029 2030
- HSIC fair value vs current price
- HSIC insider transactions and insider buying
- Is HSIC undervalued or overvalued?
- Henry Schein Inc financial analysis — revenue, earnings, cash flow
- HSIC Piotroski F-Score and Altman Z-Score
- HSIC analyst price target and Smart Rating
Henry Schein Inc
📊 No data available
Try selecting a different time range
HSIC Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Henry Schein Inc (HSIC)
HSIC is trading near its Graham intrinsic value of $93.39, suggesting the stock is reasonably priced at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Henry Schein Inc (HSIC) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, institutional own.. Concerns around return on equity and operating margin. Fundamentals are solid but monitor weak areas for improvement.
Henry Schein Inc (HSIC) Key Strengths (3)
Paying less than $1 for every $1 of annual revenue
106.64% of shares held by major funds and institutions
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Henry Schein Inc (HSIC) Areas to Watch (7)
Very thin margins with limited operational efficiency
Very thin margins, barely profitable
Low profitability relative to shareholder equity
Modest revenue growth at 7.70%
Growth is fairly priced, not cheap, not expensive
Fairly priced relative to book value
Solid earnings growth at 13.60%
Henry Schein Inc (HSIC) Detailed Analysis Report
Overall Assessment
This company scores 56/100 in our Smart Analysis, earning a C grade. Out of 10 metrics analyzed, 3 register as strengths (avg 9.0/10) while 7 fall into concern territory (avg 4.1/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Institutional Own., Market Cap. Valuation metrics including Price/Sales (0.66) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Operating Margin, Profit Margin, Return on Equity. Some valuation metrics including PEG Ratio (1.60), Price/Book (2.56) suggest expensive pricing. Growth concerns include Revenue Growth at 7.70%, EPS Growth at 13.60%, which may limit upside. Profitability pressure is visible in Return on Equity at 8.70%, Operating Margin at 5.30%, Profit Margin at 3.02%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 8.70% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 7.70% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Price/Sales, Institutional Own.) and negatives (Operating Margin, Profit Margin). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
HSIC Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
HSIC's Price-to-Sales ratio of 0.66x trades at a deep discount to its historical average of 1.71x (1th percentile). The current valuation is 75% below its historical high of 2.68x set in Jul 2016, and 2% above its historical low of 0.65x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~0.8x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Henry Schein Inc (HSIC) · HEALTHCARE › MEDICAL DISTRIBUTION
The Big Picture
Henry Schein Inc is a mature, profitable business with steady cash generation. Revenue reached 13.2B with 8% growth year-over-year. Profit margins are strong at 302.0%, reflecting pricing power and operational efficiency.
Key Findings
ROE of 870.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Generating 338M in free cash flow and 381M in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Debt management: total debt of 3.4B is significantly higher than cash (136M). Monitor refinancing risk.
Sector dynamics: monitor MEDICAL DISTRIBUTION industry trends, competitive moves, and regulatory changes that could impact Henry Schein Inc.
Bottom Line
Henry Schein Inc is a well-established business delivering consistent profitability with 302.0% margins. The growth phase may be slowing, but strong cash generation and operational efficiency make it suitable for investors seeking reliability over excitement.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(62 last 3 months)
| Insider | Type | Shares |
|---|---|---|
POPECK, THOMAS C CEO, Henry Schein Products | Sell | -1,355 |
| Insider | Type | Shares |
|---|---|---|
ETTINGER, MICHAEL S EVP & Chief Operating Officer | Sell | -1,000 |
| Insider | Type | Shares |
|---|---|---|
BERGMAN, STANLEY M Director | Sell | -970 |
| Insider | Type | Shares |
|---|---|---|
KUEHN, KURT P Director | Sell | -2,844 |
Data sourced from SEC Form 4 filings
Last updated: 8:28:11 AM
About Henry Schein Inc(HSIC)
NASDAQ
HEALTHCARE
MEDICAL DISTRIBUTION
USA
Henry Schein, Inc. is an American distributor of health care products and services with a presence in 32 countries.